Family · Pharmaceutical analytical standards
Ambrisentan
A selective antagonist of the endothelin ETA receptor, approved in 2007 in the United States and in 2008 in Europe for pulmonary arterial hypertension. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?Its target, endothelin, was discovered in 1988 by the Japanese researcher Masashi Yanagisawa and colleagues: it is a powerful vasoconstrictor made by the cells lining the blood vessels.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
